BeiGene
BGNE
#881
Rank
A$33.26 B
Marketcap
$302.96
Share price
1.71%
Change (1 day)
0.85%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: A$33.26 Billion

As of September 2024 BeiGene has a market cap of A$33.26 Billion. This makes BeiGene the world's 881th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Market cap Change
2024A$33.26 B14.35%
2023A$29.08 B-15.63%
2022A$34.47 B-8.81%
2021A$37.80 B21.23%
2020A$31.18 B113.08%
2019A$14.63 B23.75%
2018A$11.82 B107.47%
2017A$5.70 B241.11%
2016A$1.67 B

End of Day market cap according to different sources

On Sep 20th, 2024 the market cap of BeiGene was reported to be:

A$33.26 Billion
by Yahoo Finance info icon info icon
A$33.26 Billion
by CompaniesMarketCap info icon info icon
A$32.14 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Market cap Market cap differencediff. Country
A$31.35 M-99.91%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.53 B-95.38%๐Ÿ‡บ๐Ÿ‡ธ USA